[THE INVESTOR] Samsung Biologics and Sillajen are likely to be listed by the end of this year, according to analysts on July 19. Samsung Biologics is preparing to apply for preliminary assessment by the Korea Exchange by August this year. Once listed, the stock value is expected to reach around 10 trillion won (US$8.77 billion). The company posted a second straight year of loss in 2015, with the amount widening to 203.6 billion won from 119.5 billion won in 2014. Samsung Biologics headqartersAna